{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:18:34Z","timestamp":1793650714652,"version":"4.5.1"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Telethon Foundation","doi-asserted-by":"publisher","award":["GSP 21002"],"award-info":[{"award-number":["GSP 21002"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118159","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:02:50Z","timestamp":1747148570000},"page":"118159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Doxycycline: An essential tool for Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5374-3914","authenticated-orcid":false,"given":"Gianluigi","family":"Forloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118159_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.1948.tb27262.x","article-title":"Aureomycin: a product of the continuing search for new antibiotics","volume":"51","author":"Duggar","year":"1948","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib2","first-page":"18","article-title":"Tetracycline antibiotics","volume":"7","author":"Ramachanderan","year":"2021","journal-title":"Chem. Texts"},{"key":"10.1016\/j.biopha.2025.118159_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","article-title":"Clinical pharmacokinetics of doxycycline and minocycline","volume":"15","author":"Saivin","year":"1988","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118159_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10096-017-3081-x","article-title":"Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations","volume":"37","author":"Cunha","year":"2018","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117267","article-title":"Synthetic approaches and therapeutic applications of FDA-approved antibacterial agents: a comprehensive review from 2003 to 2023","volume":"285","author":"Qiao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118159_bib6","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.3390\/pharmaceutics13122085","article-title":"The development of third-generation tetracycline antibiotics and new perspectives","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118159_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1471469","article-title":"The tigecycline resistance mechanisms in Gram-negative bacilli","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.biopha.2025.118159_bib8","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1038\/s41467-024-50453-3","article-title":"A synthetic antibiotic class with a deeply-optimized design for overcoming bacterial resistance","volume":"15","author":"Feng","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118159_bib9","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.4c00912","article-title":"C10-benzoate esters of anhydrotetracycline inhibit tetracycline destructases and recover tetracycline antibacterial activity","author":"Williford","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140853","article-title":"Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor-mediated lymphangiogenesis","volume":"131","author":"Furlong-Silva","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2025.118159_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101831","article-title":"Effect of doxycyline in chronic obstructive pulmonary disease - an exploratory study","volume":"58","author":"Singh","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118159_bib12","article-title":"EffectS of Minocycline Combined with Tinidazole for Treatment of Chronic Periodontitis","volume":"44","author":"Huang","year":"2021","journal-title":"Clin. Investig. Med."},{"key":"10.1016\/j.biopha.2025.118159_bib13","first-page":"14","article-title":"Nonantibiotic properties of tetracyclines in rosacea and their clinical implications","volume":"14","author":"Del Rosso","year":"2021","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10.1016\/j.biopha.2025.118159_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1164\/rccm.202005-1916OC","article-title":"Inhibition of caspase-1 with tetracycline ameliorates acute lung injury","volume":"204","author":"Peukert","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2025.118159_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12931-022-01937-7","article-title":"Tetracycline ameliorates silica-induced pulmonary inflammation and fibrosis via inhibition of caspase-1","volume":"23","author":"Peukert","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.biopha.2025.118159_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/13543784.2022.2054325","article-title":"Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications","volume":"31","author":"Garrido-Mesa","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2025.118159_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1089\/vim.2024.0034","article-title":"Effective treatment of COVID-19 infection with repurposed drugs: case reports","volume":"37","author":"Enyeji","year":"2024","journal-title":"Viral Immunol."},{"key":"10.1016\/j.biopha.2025.118159_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00284-024-03948-7","article-title":"Repositioning of antibiotics in the treatment of viral infections","volume":"81","author":"Bustos-Hamdan","year":"2024","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.biopha.2025.118159_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/0929867013373570","article-title":"A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury","volume":"8","author":"Nieman","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118159_bib20","first-page":"474","article-title":"Do minocycline and other tetracyclines have a place in rheumatology?","volume":"64","author":"Toussirot","year":"1997","journal-title":"Rev. Rhum. Engl. Ed."},{"key":"10.1016\/j.biopha.2025.118159_bib21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/biom14121515","article-title":"Repurposing historic drugs for neutrophil-mediated inflammation in skin disorders","volume":"14","author":"Franceschin","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118159_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/antibiotics14010065","article-title":"Tetracyclines in RHeumatoid Arthritis: Dual Anti-inflammatory and Immunomodulatory Roles, Effectiveness, and Safety insights","volume":"14","author":"Radi\u0107","year":"2025","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2025.118159_bib23","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2174\/1874467214666210210122628","article-title":"Minocycline and doxycycline: more than antibiotics","volume":"14","author":"Singh","year":"2021","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s12640-019-00015-z","article-title":"The neuroprotective effect of doxycycline on neurodegenerative diseases","volume":"35","author":"Santa-Cec\u00edlia","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.biopha.2025.118159_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00702-021-02457-2","article-title":"Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease","volume":"129","author":"Markulin","year":"2022","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.biopha.2025.118159_bib26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10495-023-01848-y","article-title":"Apoptosis in Alzheimer's disease: insight into the signaling pathways and therapeutic avenues","volume":"28","author":"Kumari","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2025.118159_bib27","article-title":"Repurposing doxycycline for Alzheimer's treatment: challenges from a nano-based drug delivery perspective","volume":"42","author":"Concei\u00e7\u00e3o","year":"2024","journal-title":"Brain Behav. Immun. Health"},{"key":"10.1016\/j.biopha.2025.118159_bib28","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.70032","article-title":"Minocycline mitigates sepsis-induced neuroinflammation and promotes recovery in male mice: insights into neuroprotection and inflammatory modulation","volume":"12","author":"Hosseini","year":"2024","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.biopha.2025.118159_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2024.08.006","article-title":"Forget me not: the effect of doxycycline on human declarative memory","volume":"89","author":"Wehrli","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.111.2874.85.a","article-title":"Terramycin, a new antibiotic","volume":"11","author":"Finlay","year":"1950","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118159_bib31","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1021\/ja01139a533","volume":"74","author":"Stephens","year":"1952","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2025.118159_bib32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/ja00890a003","article-title":"The crystal structure of aureomycin (Chlortetracycline) hydrochloride. Configuration, bond distances and conformation","volume":"85","author":"Donohue","year":"1963","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2025.118159_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1021\/ja01079a034","article-title":"The stereochemistry at C-5 in oxytetracycline","volume":"87","author":"von Wittenau","year":"1965","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2025.118159_bib34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cbic.200600535","article-title":"Protonation patterns in tetracycline: tet repressor recognition: simulations and experiments","volume":"8","author":"Aleksandrov","year":"2007","journal-title":"ChemBioChem"},{"key":"10.1016\/j.biopha.2025.118159_bib35","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1021\/jm200332e","article-title":"Recognition of drug degradation products by target proteins: isotetracycline binding to Tet repressor","volume":"54","author":"Volkers","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118159_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2020.140404","article-title":"Thermodynamics, cooperativity and stability of the tetracycline repressor (TetR) upon tetracycline binding","volume":"1868","author":"Palm","year":"2020","journal-title":"Biochim Biophys. Acta Proteins Proteom."},{"key":"10.1016\/j.biopha.2025.118159_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.682682","article-title":"A complementary mechanism of bacterial mRNA translation inhibition by tetracyclines","volume":"12","author":"Barrenechea","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2025.118159_bib38","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41467-024-49797-7","article-title":"Structural basis for differential inhibition of eukaryotic ribosomes by tigecycline","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118159_bib39","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.biopha.2025.118159_bib40","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1021\/ja01552a082","article-title":"Hydrogenolysis studies in the tetracycline series\u20146-deoxytetracyclines","volume":"80","author":"Stephens","year":"1958","journal-title":"Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2025.118159_bib41","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1021\/ja00900a027","article-title":"6-Deoxytetracyclines. IV. Preparation, C-6 stereochemistry, and reactions","volume":"85","author":"Stephens","year":"1963","journal-title":"Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2025.118159_bib42","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1021\/ja00907a010","volume":"85","author":"Blackwood","year":"1963","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.biopha.2025.118159_bib43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1021\/jo00804a025","article-title":"Synthesis of 7-dimethylamino-6-demethyl-6-deoxytetracycline (minocycline) via 9-nitro-6-demethyl-6-deoxytetracycline","volume":"36","author":"Church","year":"1971","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.biopha.2025.118159_bib44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.clinthera.2006.08.011","article-title":"Tigecycline: a glycylcycline antimicrobial agent","volume":"28","author":"Doan","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2025.118159_bib45","first-page":"155","article-title":"Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics","volume":"19","author":"Greer","year":"2006","journal-title":"Proc. (Bayl. Univ. Med Cent."},{"key":"10.1016\/j.biopha.2025.118159_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.12688\/f1000research.141535.1","article-title":"Evaluation of role of Tigecycline among clinically significant multidrug resistant pathogens from a tertiary care hospital","volume":"13","author":"Remash","year":"2024","journal-title":"F1000Res"},{"key":"10.1016\/j.biopha.2025.118159_bib47","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-025-05048-1","article-title":"Pathogenic characterization and drug resistance of neonatal sepsis in China: a systematic review and meta-analysis","author":"Wu","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.engmic.2024.100165","article-title":"Mechanisms of tigecycline resistance in Gram-negative bacteria: a narrative review","volume":"4","author":"Su","year":"2024","journal-title":"Eng. Microbiol."},{"key":"10.1016\/j.biopha.2025.118159_bib49","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/biom14101263","article-title":"Mechanistic insights into clinically relevant ribosome-targeting antibiotics","volume":"14","author":"Krawczyk","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118159_bib50","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11033-024-09380-1","article-title":"Minocycline induced apoptosis and suppressed expression of matrix metalloproteinases 2 and 9 in the breast cancer MCF-7 cells","volume":"51","author":"Rezaei","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2025.118159_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175949","article-title":"Tetracycline antibiotics: potential anticancer drugs","volume":"956","author":"Li","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12885-024-12064-5","article-title":"Regulation of metastatic potential by drug repurposing and mitochondrial targeting in colorectal cancer cells","volume":"24","author":"Mathur","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2025.118159_bib53","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8659802","article-title":"Minocycline in treating glioblastoma multiforme: far beyond a conventional antibiotic","author":"Afshari","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.biopha.2025.118159_bib54","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1002\/bit.28527","article-title":"The application of electrosprayed minocycline-loaded PLGA microparticles for the treatment of glioblastoma","volume":"120","author":"Arriaga","year":"2023","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.biopha.2025.118159_bib55","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s00210-023-02839-1","article-title":"Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review","volume":"397","author":"Rezaei","year":"2024","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FBP.0000000000000754","article-title":"Minocycline as a potential anxiolytic drug: systematic review and meta-analysis of evidence in murine models","volume":"35","author":"Iglesias","year":"2024","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11126-019-09707-3","article-title":"Minocycline for depressive symptoms: a meta-analysis of randomized, double-blinded, placebo-controlled trials","volume":"91","author":"Cai","year":"2020","journal-title":"Psychiatr. Q"},{"key":"10.1016\/j.biopha.2025.118159_bib58","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.3390\/ijms24065250","article-title":"Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis","volume":"24","author":"Panizzutti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib59","article-title":"Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials","author":"Lanzenberger","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2025.118159_bib60","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1111\/j.0953-816X.2004.03439.x","article-title":"Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning","volume":"19","author":"Hunter","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118159_bib61","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/sj.npp.1301377","article-title":"Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models","volume":"32","author":"Choi","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2025.118159_bib62","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/glia.20338","article-title":"Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice","volume":"53","author":"Seabrook","year":"2006","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118159_bib63","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1523\/JNEUROSCI.4371-06.2007","article-title":"Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid","volume":"27","author":"Fan","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2025.118159_bib64","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1096\/fj.08-113795","article-title":"Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease","volume":"23","author":"Noble","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118159_bib65","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","article-title":"Minocycline in Alzheimer disease efficacy (MADE) Trialist Group. Minocycline at 2 different dosages vs placebo for patients with mild alzheimer disease: a randomized clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.biopha.2025.118159_bib66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/01616412.2023.2296754","article-title":"Minocycline mitigates tau pathology via modulating the TLR-4\/NF-\u043a\u03b2 signalling pathway in the hippocampus of neuroinflammation rat model","volume":"46","author":"Abdo Qaid","year":"2024","journal-title":"Neurol. Res."},{"key":"10.1016\/j.biopha.2025.118159_bib67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3233\/JAD-230151","article-title":"Inhibition of pro-inflammatory microglia with minocycline improves cognitive and sleep-wake dysfunction under respiratory stress in a sporadic model for Alzheimer's disease","volume":"95","author":"Vicente","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2022.102158","article-title":"The effect of minocycline on beta-amyloid-induced memory and learning deficit in male rats: a behavioral, biochemical, and histological study","volume":"125","author":"Gholami Mahmoudian","year":"2022","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.biopha.2025.118159_bib69","doi-asserted-by":"crossref","DOI":"10.1007\/s10787-022-01071-2","article-title":"Minocycline attenuates cholinergic dysfunction and neuro-inflammation-mediated cognitive impairment in scopolamine-induced Alzheimer's rat model","author":"Amirahmadi","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.biopha.2025.118159_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175784","article-title":"Minocycline effects on memory and learning impairment in the beta-amyloid-induced Alzheimer's disease model in male rats using behavioral, biochemical, and histological methods","volume":"953","author":"Gholami Mahmoudian","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib71","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbi.2022.10.009","article-title":"Prevention of microgliosis halts early memory loss in a mouse model of Alzheimer's disease","volume":"107","author":"Kater","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.biopha.2025.118159_bib72","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3233\/JAD-2011-101839","article-title":"The \u03b3-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice","volume":"24","author":"Balducci","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.110152","article-title":"Minocycline mitigates A\u03b2 and TAU pathology, neuronal dysfunction, and death in the PSEN1 E280A cholinergic-like neurons model of familial Alzheimer's disease","volume":"261","author":"Giraldo-Berrio","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118159_bib74","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41398-020-0818-6","article-title":"A single administration of the antibiotic, minocycline, reduces fear processing and improves implicit learning in healthy volunteers: analysis of the serum metabolome","volume":"10","author":"Chan","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118159_bib75","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1089\/neu.2009.1223","article-title":"Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study","volume":"27","author":"Homsi","year":"2010","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.biopha.2025.118159_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113816","article-title":"Delayed dosing of minocycline plus N-acetylcysteine reduces neurodegeneration in distal brain regions and restores spatial memory after experimental traumatic brain injury","volume":"345","author":"Whitney","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2025.118159_bib77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7150\/ijbs.64187","article-title":"Minocycline improves the functional recovery after traumatic brain injury via inhibition of aquaporin-4","volume":"18","author":"Lu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib78","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/brain\/awx339","article-title":"Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration","volume":"14","author":"Scott","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2025.118159_bib79","first-page":"1086","article-title":"Effects of minocycline on neurological outcomes in patients with acute traumatic brain injury: a pilot study","volume":"18","author":"Koulaeinejad","year":"2019","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.biopha.2025.118159_bib80","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s13311-023-01426-9","article-title":"Treating traumatic brain injury with minocycline","volume":"20","author":"Bergold","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.biopha.2025.118159_bib81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12868-024-00851-6","article-title":"Current state of neuroprotective therapy using antibiotics in human traumatic brain injury and animal models","volume":"25","author":"Ritter","year":"2024","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.biopha.2025.118159_bib82","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1089\/089771503770195867","article-title":"Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat","volume":"20","author":"Lee","year":"2003","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.biopha.2025.118159_bib83","first-page":"1628","article-title":"VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice","volume":"26","author":"Hurlbert","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2025.118159_bib84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2015.10.015","article-title":"Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury","volume":"75","author":"Papa","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2025.118159_bib85","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/nn4036014","article-title":"Selective nanovector mediated treatment of activated proinflammatory microglia\/macrophages in spinal cord injury","volume":"7","author":"Papa","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2025.118159_bib86","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1039\/D4NA00625A","article-title":"Preparation of a minocycline polymer micelle thermosensitive gel and its application in spinal cord injury","volume":"6","author":"Gu","year":"2024","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.biopha.2025.118159_bib87","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/aws072","article-title":"Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury","volume":"135","author":"Casha","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2025.118159_bib88","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1089\/neu.2018.5899","article-title":"Cerebrospinal fluid biomarkers in human spinal cord injury from a phase II minocycline trial","volume":"35","author":"Casha","year":"2018","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.biopha.2025.118159_bib89","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1227\/00006123-200106000-00051","article-title":"Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction","volume":"48","author":"Sanchez Mejia","year":"2001","journal-title":"Neurosurgery"},{"key":"10.1016\/j.biopha.2025.118159_bib90","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/BSD.0000000000000861","article-title":"Neuroprotective agents as an adjuvant treatment in patients with acute spinal cord injuries: a qualitative systematic review of randomized trials","volume":"33","author":"Joaquim","year":"2020","journal-title":"Clin. Spine Surg."},{"key":"10.1016\/j.biopha.2025.118159_bib91","doi-asserted-by":"crossref","DOI":"10.2174\/1570159X23666250313104646","article-title":"Exploring the effectiveness and potential pharmacological mechanism of minocycline for spinal cord injury through meta-analysis and network pharmacology","author":"Hu","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib92","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/BSD.0000000000001695","article-title":"Pharmacologic therapy for spinal cord injury","volume":"37","author":"Sherrod","year":"2024","journal-title":"Clin. Spine Surg."},{"key":"10.1016\/j.biopha.2025.118159_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-200723","article-title":"Doxycycline and suicidality","volume":"2013","author":"Atigari","year":"2013","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.biopha.2025.118159_bib94","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.brainresbull.2018.02.007","article-title":"Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways","volume":"139","author":"Ben-Azu","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.biopha.2025.118159_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114764","article-title":"The antidepressant-like effect of doxycycline is associated with decreased nitric oxide metabolite levels in the prefrontal cortex","volume":"458","author":"Sales","year":"2024","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2025.118159_bib96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.euroneuro.2020.11.007","article-title":"Doxycycline reverses cognitive impairment, neuroinflammation and oxidative imbalance induced by D-amphetamine mania model in mice: a promising drug repurposing for bipolar disorder treatment?","volume":"42","author":"Chaves Filho","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib97","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1006\/jmbi.2000.3840","article-title":"Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro","volume":"300","author":"Tagliavini","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118159_bib98","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","article-title":"Anti-amyloidogenic activity of tetracyclines: studies in vitro","volume":"487","author":"Forloni","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2025.118159_bib99","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1021\/jm400161p","article-title":"A new face for old antibiotics: tetracyclines in treatment of amyloidoses","volume":"56","author":"Stoilova","year":"2013","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118159_bib100","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.3390\/ijms20184641","article-title":"The anti-amyloidogenic action of doxycycline: a molecular dynamics study on the interaction with A\u03b242","volume":"20","author":"Gautieri","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.822420","article-title":"Oligomeropathies, inflammation and prion protein binding","volume":"16","author":"Forloni","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2025.118159_bib102","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0092-8674(93)90635-4","article-title":"Seeding \"one-dimensional crystallization\" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?","volume":"73","author":"Jarrett","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118159_bib103","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1073\/pnas.90.13.5959","article-title":"A kinetic model for amyloid formation in the prion diseases: importance of seeding","volume":"90","author":"Come","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118159_bib104","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.26624","article-title":"Oligomeropathies and pathogenesis of Alzheimer and Parkinson\u2019s diseases","volume":"31","author":"Forloni","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2025.118159_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.635760","article-title":"Doxycycline interferes with Tau aggregation and reduces its neuronal toxicity","volume":"13","author":"Medina","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.biopha.2025.118159_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/srep41755","article-title":"Repurposing doxycycline for synucleinopathies: remodelling of \u03b1-synuclein oligomers towards non-toxic parallel beta-sheet structured species","volume":"7","author":"Gonz\u00e1lez-Liz\u00e1rraga","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118159_bib107","article-title":"C9-FUnctionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological \u03b1-Synuclein Aggregation and Neuroinflammation in Parkinson's disease degeneration","volume":"19","author":"Rose","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2025.118159_bib108","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neurobiolaging.2018.06.002","article-title":"Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models","volume":"70","author":"Balducci","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.biopha.2025.118159_bib109","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3389\/fphar.2019.00738","article-title":"Doxycycline for Alzheimer's disease: fighting \u03b2-amyloid oligomers and neuroinflammation","volume":"10","author":"Balducci","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib110","first-page":"3468","article-title":"A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat","volume":"19","author":"Zhang","year":"2015","journal-title":"Eur. Rev. Med Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib111","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/SHK.0000000000000556","article-title":"Doxycycline attenuates lipopolysaccharide-induced microvascular endothelial cell derangements","volume":"45","author":"Wiggins-Dohlvik","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.biopha.2025.118159_bib112","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jad.2021.05.083","article-title":"Doxycycline at subantimicrobial dose combined with escitalopram reverses depressive-like behavior and neuroinflammatory hippocampal alterations in the lipopolysaccharide model of depression","volume":"292","author":"Mello","year":"2021","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.biopha.2025.118159_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108999","article-title":"Impact of chronic doxycycline treatment in the APP\/PS1 mouse model of Alzheimer's disease","volume":"209","author":"Gomez-Murcia","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2025.118159_bib114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11481-024-10099-w","article-title":"Doxycycline-loaded calcium phosphate nanoparticles with a pectin coat can ameliorate lipopolysaccharide-induced neuroinflammation via enhancing AMPK","volume":"19","author":"Morsy","year":"2024","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","article-title":"A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease","volume":"52","author":"Loeb","year":"2004","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.biopha.2025.118159_bib116","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","article-title":"DARAD Study Group. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial","volume":"28","author":"Molloy","year":"2013","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118159_bib117","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V86.3.855.855","article-title":"New drug therapy of amyloidoses: resorption of AL-type deposits with 4\u2032-iodo-4\u2032-deoxydoxorubicin","volume":"86","author":"Gianni","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118159_bib118","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1006\/jmbi.2000.3840","article-title":"Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro","volume":"300","author":"Tagliavini","year":"2000","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118159_bib119","doi-asserted-by":"crossref","first-page":"10849","DOI":"10.1073\/pnas.162195499","article-title":"Tetracyclines affect prion infectivity","volume":"99","author":"Forloni","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118159_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001888","article-title":"The efficacy of tetracyclines in peripheral and intracerebral prion infection","volume":"3","author":"De Luigi","year":"2008","journal-title":"PLOS One"},{"key":"10.1016\/j.biopha.2025.118159_bib121","doi-asserted-by":"crossref","unstructured":"Tagliavini F., Prion therapy: Tetracyclic compounds in animal models and patients with Creutzfeldt-Jakob disease 4, Issue 4S_Part_5.","DOI":"10.1016\/j.jalz.2008.05.373"},{"key":"10.1016\/j.biopha.2025.118159_bib122","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/jnnp-2016-313541","article-title":"Doxycycline in early CJD: a double-blinded randomised phase II and observational study","volume":"88","author":"Varges","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118159_bib123","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Ha\u00efk","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2025.118159_bib124","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/19336896.2015.1027857","article-title":"Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases","volume":"9","author":"Forloni","year":"2015","journal-title":"Prion"},{"key":"10.1016\/j.biopha.2025.118159_bib125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/19336896.2022.2083435","article-title":"Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement","volume":"16","author":"Forloni","year":"2022","journal-title":"Prion"},{"key":"10.1016\/j.biopha.2025.118159_bib126","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-024-00497-y","article-title":"Creutzfeldt-Jakob disease and other prion diseases","volume":"10","author":"Zerr","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118159_bib127","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3233\/JAD-170819","article-title":"Alzheimer's disease, oligomers, and inflammation","volume":"62","author":"Forloni","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib128","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.118159_bib129","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.3390\/ijms24065914","article-title":"Alpha synuclein: neurodegeneration and inflammation","volume":"24","author":"Forloni","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib130","article-title":"Chemokines in neurodegenerative diseases","author":"Vida","year":"2024","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118159_bib131","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3267172","article-title":"Resolution of inflammation in neurodegenerative diseases: the role of resolvins","volume":"2020","author":"Chamani","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2025.118159_bib132","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.biopha.2025.118159_bib133","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12640-009-9078-1","article-title":"Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3","volume":"16","author":"Cho","year":"2009","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.biopha.2025.118159_bib134","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/glia.22496","article-title":"Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model","volume":"61","author":"Lazzarini","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2025.118159_bib135","first-page":"3468","article-title":"A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat","volume":"19","author":"Zhang","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1045465","article-title":"Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model","volume":"13","author":"Dos Santos Pereira","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib137","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/bs.pmbts.2020.11.001","article-title":"Inflammation and Parkinson's disease pathogenesis: mechanisms and therapeutic insight","volume":"177","author":"Forloni","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2022.105229","article-title":"Repositioning doxycycline for treating synucleinopathies: evidence from a pre-clinical mouse model","volume":"106","author":"La Vitola","year":"2023","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.biopha.2025.118159_bib139","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118159_bib140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118159_bib141","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2025.118159_bib142","article-title":"Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity","volume":"103","author":"Zhang","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.biopha.2025.118159_bib143","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese patients with early alzheimer's disease: subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2025.118159_bib144","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0088-24.2024","article-title":"What's in It for Me? Contextualizing the potential clinical impacts of lecanemab, donanemab, and other anti-\u03b2-amyloid monoclonal antibodies in early Alzheimer's disease","volume":"11","author":"Jin","year":"2024","journal-title":"eNeuro"},{"key":"10.1016\/j.biopha.2025.118159_bib145","article-title":"Perspectives on the clinical use of anti-amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology","volume":"10","author":"Jicha","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.biopha.2025.118159_bib146","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","article-title":"Quality Committee. Antiamyloid monoclonal antibody therapy for alzheimer disease: emerging issues in neurology","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2025.118159_bib147","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1126\/science.adu2383","article-title":"Alzheimer's drug approvals create prescribing dilemmas","volume":"386","author":"Couzin-Frankel","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118159_bib148","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial Experience with lecanemab and lessons learned in 71 patients in a regional medical center","volume":"11","author":"Shields","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib149","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.biopha.2025.118159_bib150","article-title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: a systematic review and meta-analysis","volume":"104","author":"Arroyo-Pacheco","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.biopha.2025.118159_bib151","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.biopha.2025.118159_bib152","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","article-title":"Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability","volume":"4","author":"Therriault","year":"2024","journal-title":"Nat. Aging"},{"key":"10.1016\/j.biopha.2025.118159_bib153","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118159_bib154","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16534","article-title":"Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: a simultaneous real-word study on aducanumab and lecanemab","volume":"32","author":"Logroscino","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.biopha.2025.118159_bib155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000079","article-title":"Alzheimer's disease: from basic science to precision medicine approach","volume":"2","author":"Forloni","year":"2020","journal-title":"BMJ Neurol. Open"},{"key":"10.1016\/j.biopha.2025.118159_bib156","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12974-024-03163-y","article-title":"Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?","volume":"21","author":"Lista","year":"2024","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2025.118159_bib157","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1002\/alz.14063","article-title":"Pathways to personalized medicine-Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease","volume":"20","author":"Arnold","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.biopha.2025.118159_bib158","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3390\/brainsci14121266","article-title":"Artificial intelligence-based methodologies for early diagnostic precision and personalized therapeutic strategies in neuro-ophthalmic and neurodegenerative pathologies","volume":"14","author":"Kumar","year":"2024","journal-title":"Brain Sci."},{"key":"10.1016\/j.biopha.2025.118159_bib159","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/alz.13392","article-title":"CCR5 deficiency: Decreased neuronal resilience to oxidative stress and increased risk of vascular dementia","volume":"20","author":"Tournier","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.biopha.2025.118159_bib160","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1192\/bjp.2024.122","article-title":"Disease trajectories before dementia: evidence from a large-scale community-based prospective study","volume":"225","author":"Li","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118159_bib161","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41398-024-03155-9","article-title":"PACt-MD Study Group. Exploring mitochondrial blood-based and genetic markers in older adults with mild cognitive impairment and remitted major depressive disorder","volume":"14","author":"Choi","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118159_bib162","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12031-024-02291-7","article-title":"Precision prediction of Alzheimer's disease: integrating mitochondrial energy metabolism and immunological insights","volume":"75","author":"Du","year":"2025","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2025.118159_bib163","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-024-02862-5","article-title":"Sex differences in mitochondrial free-carnitine levels in subjects at-risk and with Alzheimer's disease in two independent study cohorts","author":"Bigio","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118159_bib164","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13195-024-01651-0","article-title":"Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease","volume":"17","author":"Huang","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.biopha.2025.118159_bib165","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2174\/1570159X22666240426091311","article-title":"Drug target to alleviate mitochondrial dysfunctions in Alzheimer's disease: recent advances and therapeutic implications","volume":"22","author":"Rahman","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib166","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41598-025-85947-7","article-title":"DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer's disease","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118159_bib167","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2025.118159_bib168","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","article-title":"Alzheimer disease as a clinical-biological construct-an international working group recommendation","volume":"81","author":"Dubois","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.biopha.2025.118159_bib169","article-title":"CSF inflammatory cytokines as prognostic indicators for cognitive decline across Alzheimer's disease spectrum","volume":"2024","author":"Ghanbarian","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2025.118159_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100018","article-title":"Genetic predisposition to high circulating levels of interleukin 6 and risk for Alzheimer's disease. Discovery and replication","volume":"12","author":"Charisis","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102257","article-title":"Circulating biomarkers of inflammaging and Alzheimer's disease to track age-related trajectories of dementia: Can we develop a clinically relevant composite combination?","volume":"96","author":"Abbatecola","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.biopha.2025.118159_bib172","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.3390\/nu13092971","article-title":"Changes in gut microbiota induced by doxycycline influence in vascular function and development of hypertension in DOCA-salt rats","volume":"13","author":"Robles-Vera","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2025.118159_bib173","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/life14121555","article-title":"Therapeutic options in alzheimer's disease: from classic acetylcholinesterase inhibitors to multi-target drugs with pleiotropic activity","volume":"14","author":"Cacabelos","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.biopha.2025.118159_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115094","article-title":"Advances in peripheral blood biomarkers of patients with Alzheimer's disease: moving closer to personalized therapies","volume":"165","author":"Ferretti","year":"2023","journal-title":"Biomed. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118159_bib175","unstructured":"EMA, 2019, Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. Available: \u3008https:\/\/www\u3009. ema. europa. eu\/."},{"key":"10.1016\/j.biopha.2025.118159_bib176","doi-asserted-by":"crossref","first-page":"164","DOI":"10.14283\/jpad.2019.12","article-title":"Combination therapy for Alzheimer's disease: perspectives of the EU\/US CTAD task force","volume":"6","author":"Gauthier","year":"2019","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118159_bib177","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40263-024-01103-1","article-title":"Alzheimer's disease: combination therapies and clinical trials for combination therapy development","volume":"38","author":"Cummings","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopha.2025.118159_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100001","article-title":"Key considerations for combination therapy in Alzheimer's clinical trials: perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation","volume":"12","author":"Cummings","year":"2025","journal-title":"J. Prev. Alzheimer Dis."},{"issue":"13","key":"10.1016\/j.biopha.2025.118159_bib179","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1021\/acs.jmedchem.2c00205","article-title":"Innovative non-PrP-targeted drug strategy designed to enhance prion clearance","volume":"65","author":"Colini Baldeschi","year":"2022","journal-title":"J. Med. Chem."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2025.118159_bib180","article-title":"Bifunctional carbazole derivatives for simultaneous therapy and fluorescence imaging in prion disease murine cell models","volume":"245","author":"Staderini","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118159_bib181","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nchembio.246","article-title":"A synergistic small-molecule combination directly eradicates diverse prion strain structures","volume":"5","author":"Roberts","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2025.118159_bib182","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.118.252064","article-title":"Plasma and brain concentrations of doxycycline after single and repeated doses in wild-type and APP23 mice","volume":"368","author":"Lucchetti","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:41:45Z","timestamp":1758123705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":182,"alternative-id":["S0753332225003531"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118159","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doxycycline: An essential tool for Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118159"}}